Log In
Print
BCIQ
Print
Print this Print this
 

Cortiment MMX, Uceris (Budesonide MMX)

  Manage Alerts
Collapse Summary General Information
Company Cosmo Pharmaceuticals S.A.
DescriptionBudesonide delivered using MMX multi-matrix system technology
Molecular Target Glucocorticoid receptor (GCCR)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat active mild to moderate ulcerative colitis in adults; Treat micoscopic colitis; Treat pediatric ulcerative colitis (UC); Treat ulcerative colitis (UC)
Regulatory Designation

Partner

Ferring Pharmaceuticals A/S


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$2,600.0M

$2,600.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today